Buch, Englisch, Band 113, 350 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 552 g
Reihe: Experientia Supplementum
Buch, Englisch, Band 113, 350 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 552 g
Reihe: Experientia Supplementum
ISBN: 978-3-030-91313-7
Verlag: Springer International Publishing
Since immunotherapy is an attractive approach to cancer therapy, this book also provides information on the two main strategies: monoclonal antibodies and adaptive T cell immunotherapy, with a focus on recent human clinical trials. A newly added chapter also focuses on the role of Natural Killer cells in tumor progression.
The book provides a state-of-the-art, comprehensive overview of immune cells in cancer and is an indispensable resource for researchers and practitioners working or lecturing in the field of cancer research and immunology.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
Weitere Infos & Material
Chapter 1: Cancer immunoediting - elimination, equilibrium and immune escape in solid tumors.- Chapter 2: Tumor – Stroma Interaction and Cancer. - Chapter 3: Tumor-infiltrating lymphocytes and their role in solid tumor progression.- Chapter 4: Tumor-associated macrophages – reasons to be cheerful, reasons to be fearful.- Chapter 5: Polymorphonuclear neutrophils and tumors: friend or foe?.- Chapter 6: Role of NK cells in tumor progression.- Chapter 7: The role of myeloid-derived suppressor cells in tumor growth and metastasis.- Chapter 8: Cancer stem cells – an ever hiding foe.- Chapter 9: Adoptive T-cell immunotherapy – Perfecting self-defenses.- Chapter 10: Monoclonal antibodies to CTLA-4 with focus on ipilimumab.